PTC Therapeutics, Inc.

PTC Therapeutics presented an update of its Phase II study of PTC518 (votoplam) in Huntington’s disease with data from more patients and over a longer duration of therapy on 5 May, but investors and a

Biopharma merger and acquisition value for the fourth quarter of 2024 reached $9.4bn from 34 transactions, 15 of which had disclosed values. At the top was H. Lundbeck’s $2.6bn purchase of publicly tr

The European Medicines Agency was this week deciding whether the planned EU marketing authorization applications (MAAs) for three investigational products deserved accelerated assessments – apitegroma

When Zevra Therapeutics, then known as KemPharm, bought arimoclomol for peanuts with its acquisition of Orphazyme in 2022, it looked like a great bit of business and further confirmation has come wi